Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
Sell
32
CTOR Quote, Financials, Valuation and Earnings
Last price:
$0.90
Seasonality move
:
-39.85%
Day range:
$0.83 - $0.91
52-week range:
$0.55 - $49.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.81x
Volume:
24K
Avg. volume:
57.3K
1-year change:
-92.08%
Market cap:
$64.4M
Revenue:
--
EPS (TTM):
-$0.33
Analysts' Opinion
-
Consensus RatingCitius Oncology has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.00, Citius Oncology has an estimated upside of 233.33% from its current price of $0.90.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $0.90.
Fair Value
-
According to the consensus of 1 analyst, Citius Oncology has 233.33% upside to fair value with a price target of $3.00 per share.
CTOR vs. S&P 500
-
Over the past 5 trading days, Citius Oncology has underperformed the S&P 500 by -2.93% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Citius Oncology does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Citius Oncology has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Citius Oncology reported revenues of --.
Earnings Growth
-
Citius Oncology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Citius Oncology reported earnings per share of -$0.11.
Enterprise value:
68.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -$23.1M | -$4.7M | -$7.5M | |
| EBITDA | -- | -- | -$23.1M | -$4.7M | -$7.5M | |
| Diluted EPS | -- | -- | -$0.33 | -$0.07 | -$0.11 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | $18M | |
| Total Assets | -- | -- | -- | -- | $91.4M | |
| Current Liabilities | -- | -- | -- | -- | $49.7M | |
| Total Liabilities | -- | -- | -- | -- | $55.8M | |
| Total Equity | -- | -- | -- | -- | $35.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
CTOR
Sector
Market Cap
$64.4M
$33.4M
Price % of 52-Week High
1.84%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-92.08%
-40%
Beta (5-Year)
--
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.90
200-day SMA
Sell
Level
$1.16
Bollinger Bands (100)
Sell
Level
0.71 - 1.19
Chaikin Money Flow
Sell
Level
-69.2M
20-day SMA
Buy
Level
$0.89
Relative Strength Index (RSI14)
Buy
Level
56.56
ADX Line
Buy
Level
27.92
Williams %R
Neutral
Level
-40
50-day SMA
Buy
Level
$0.78
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
171M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Stock Forecast FAQ
In the current month, CTOR has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CTOR average analyst price target in the past 3 months is $3.00.
-
Where Will Citius Oncology Stock Be In 1 Year?
According to analysts, the consensus estimate is that Citius Oncology share price will rise to $3.00 per share over the next 12 months.
-
What Do Analysts Say About Citius Oncology?
Analysts are divided on their view about Citius Oncology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Citius Oncology is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Citius Oncology's Price Target?
The price target for Citius Oncology over the next 1-year time period is forecast to be $3.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CTOR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Citius Oncology is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of CTOR?
You can purchase shares of Citius Oncology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Citius Oncology shares.
-
What Is The Citius Oncology Share Price Today?
Citius Oncology was last trading at $0.90 per share. This represents the most recent stock quote for Citius Oncology. Yesterday, Citius Oncology closed at $0.90 per share.
-
How To Buy Citius Oncology Stock Online?
In order to purchase Citius Oncology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
